Initial axonal lesion in multiple sclerosis. Reasons for early treatment;Lesión axonal inicial en la esclerosis múltiple. Razones para un tratamiento precoz

Revista de Neurologia

Volumn 35, Issue 3, 2002, Pages 221-227

  Álvarez Cermeño, José Carlos ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Axonal lesion; Beta interferon; Early treatment; Multiple sclerosis

Indexed keywords

BETA INTERFERON;

DEMYELINATING DISEASE; DIAGNOSTIC ACCURACY; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PROGNOSIS; REVIEW; TREATMENT PLANNING;

EID: 0036705017     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3503.2002328     Document Type: Review

References (100)

1. Charcot M. Histologie de la sclerose en plaques. Gaz Hosp 1868; 141: 554-5.
2. Greenfield JG, King LS. Observations on the histopathology of the cerebral lesions in disseminated sclerosis. Brain 1936; 59: 445-58.
3. Filippi M. In vivo tissue characterization of multiple sclerosis and other white matter diseases using magnetic resonance based techniques. J Neurol 2001; 248: 1019-29.
4. Bjartmar C, Battistuta J, Terada N, Dupree E, Trapp BD. N-acetyl-aspartate is an axon-specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 2002; 51: 51-8.
5. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49-58.
6. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995; 34: 721-7.
7. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43: 56-71.
8. 1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999; 46: 79-87.
9. 1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996; 47: 1469-76.
10. 1-weighted spin-echo magnetic resonance imaging. Arch Neurol 2001; 58: 76-81.
11. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-64.
12. Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath IH. Neurology 1999; 53: 751-7.
13. 1 hypointense lesions in relapsing MS. MSCRG trial of interferon β-1a. Neurology 2000; 55: 185-92.
14. Brex PA, Gómez-Ansón B, Parker GJ, Molyneux PD, Miszkiel KA, BarkeR GJ, et al. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Sci 1999; 166: 16-22.
15. 1-weghted spin-echo magnetic resonance images in multiple sclerosis. Relation to inflammatory activity. Arch Neurol 1999; 56: 345-51.
16. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-38.
17. Saindane AM, Ge Y, Udupa JK, Babb JS, Mannon LJ, Grossman RI. The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS. Neurology 2000; 55: 61-5.
18. Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-93.
19. 1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50: 1282-8.
20. Van Waesberghe JHTM, Kamphorst W, de Groot CJA, van Walderveen MAA, Castelijns JA, Ravid R, et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46: 747-54.
21. Fu L, Matthews PM, de Stefano NK, Worsley KJ, Narayanan S, Francis GS, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121: 103-13.
22. Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 118: 1583-92.
23. Filippi M, Tortorella C, Bozzali M. Normal-appearing white matter changes in multiple sclerosis: The contribution of magnetic resonance techniques. Mult Scler 1999; 5: 273-82.
24. Simon JH, Kinkel RP, Jacobs L, Bub L, Simonian N. A Wallerian degeneration pattern in patients at risk for MS. Neurology 2000; 54: 1155-60.
25. De Stefano N, Matthews PM, Antel J, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995; 38: 901-9.
26. Lee MA, Blamire AM, Pendlebury S, Ho K-H, Mills KR, Styles P, et al. Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Arch Neurol 2000; 57: 65-70.
27. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65-70.
28. Matthews PM, Pioro E, Narayanan S, De Stefano N, Fu L, Francis G, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996; 119: 715-22.
29. Tourbah A, Stievenart JL, Gout O, Fontaine B, Liblau R, Lubetzki C, et al. Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis. Neurology 1999; 53: 1091-7.
30. Trojano M, Liguori M, Zimatore GB, Bugerini R, Abolió C, Paolicelli D, et al Age-related disability in multiple sclerosis. Ann Neurol 2002; 51: 475-80.
31. Villar LV, Masjuan J, González-Porqué P, Plaza P, Sádaba MC, Roldán E, et al. Intrathecal IgM synthesis in neurological diseases: Relationship with disability in MS. Neurology 2002; 58: 824-6.
32. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996; 119: 2009-19.
33. Fox NC, Jenkins R, Leary SM, Stevenson VL, Losseff NA, Crum WR, et al. Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI. Neurology 2000; 54: 807-12.
34. Brex PA, Jenkins R, Fox NC, Crum WR, O'Riordan JI, Plant GT, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000; 54: 1689-91.
35. Stevenson VL, Leary SM, Losseff NA, Parker GJ, Barker GJ, Husmani Y, et al. Spinal cord atrophy and disability in MS: A longitudinal study. Neurology 1998; 51: 234-8.
36. Edwards SG, Liu C, Blumhardt LD. Cognitive correlates of supratentorial atrophy on MRI in multiple sclerosis. Acta Neurol Scand 2001; 104: 214-23.
37. Benedict RH, Bakshi R, Simon JH, Priore R, Miller C, Munschauer FJ. Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. Neuropsychiatr Clin Neurosci 2002; 14: 44-51.
38. Bermel RA, Bakshi R, Tjoa C, Puli SR, Jacobs L. Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis. Arch Neurol 2002; 59: 275-80.
39. Barkhof FJ, Elton M, Lindeboom J, Tas MW, Schmidt WF, Hommes OR, et al. Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI study. J Neurol 1998; 245: 153-8.
40. Pelletier J, Suchet L, Witjas T, Habib M, Gutamann CR, Salamon G, et al. A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. Arch Neurol 2001; 58: 105-11.
41. Coles AJ, Wing MG, Molyneaux P, Paolillo A, Davie CM, Hale G, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304.
42. Lin X, Blumhardt LD. Inflammation and atrophy in multiple sclerosis: MRI associations with disease course. J Neurol Sci 2001; 189: 99-104.
43. Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125: 327-37.
44. Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B, et al. Relationship between brain atrophy and disability: An 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000; 6:373-77.
45. Lassmann H, Suchaneck G, Ozawa K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 1994; 36: S42-6.
46. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.
47. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
48. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Size-selective changes in the anterior optic pathways suggest a differential susceptibility to injury in multile sclerosis. Brain 2001; 124: 1813-20.
49. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Brück W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123: 1174-83.
50. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000; 47: 391-5.
51. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000; 123: 1845-9.
52. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 2001; 57: 1248-52.
53. Giordana MT, Richiardi P, Trevisan E, Boghi A, Palmucci L. Abnormal ubiquitination of the axons in normally myelinated white matter in múltiple sclerosis brain. Neuropathol Appl Neurobiol 2002; 28: 35-41.
54. McGavern DB, Murray PD, Rivera-Quiñones C, Schmelzer JD, Low PA, Rodriguez M. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis Brain 2000; 123: 519-31.
55. Bjartmar C, Kidd G, Mörk S, Rudick RA, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893-901.
56. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996; 6: 259-74.
57. Hemmer B, Archelos JJ, Hartung H-P. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3: 291-301.
58. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37: 424-35.
59. Baranzini SE, Elfstrom C, Chang S-Y, Butunoi C, Murray R, Higuchi R, Oksenberg J. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol 2000; 165: 6576-82.
60. Sharief MK, Thompson EJ. In vivo relationship of tumor necrosis factor-α to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol 1992; 38: 27-34.
61. Gimsa U, Peter SV, Lehmann K, Bechmann I, Nitsch R. Axonal damage induced by invading T cells in organotypic central nervous system tissue in vitro: Involvement of microglial cells. Brain Pathol 2000; 10: 365-77.
62. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325: 467-72.
63. Sriram S, Rodríguez M. Indictment of the microglia as the villain in multiple sclerosis. Neurology 1997; 48: 464-70.
64. Kieiseier BC, Storch MK, Archelos JJ, Martino G, Hartung H-P. Effector pathways in immune mediated central nervous system demyelination. Curr Opin Neurol 1999; 12: 323-36.
65. Newman TA, Woolley ST, Hughes PM, Sibson NR, Anthony DC, Perry VH. T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: Involvement of metalloproteinases. Brain 2001; 124: 2203-14.
66. Scarisbrick IA, Blaber SI, Lucchinetti CF, Genain CP, Blaber M, Rodríguez M. Activity of a newly identified serine protease in CNS demyelination, Brain 2002; 125: 1283-96.
67. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001; 49: 470-6.
68. Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 1998; 88: 45-56.
69. Abedin KJ, Papadopoulos D, Dexter DT, Reynolds R. Oxidative DNA damage in the spinal cord in multiple sclerosis. Neuropathol Appl Neurobiol 2002; 28: 168.
70. Matute C. Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve. Proc Natl Acad Sci U S A 1998; 95: 10229-34.
71. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000; 6: 67-70.
72. Werner P, Pitt D, Raine CS. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001; 50: 169-80.
73. Alcázar A, Regidor I, Masjuan J, Salinas M, Álvarez-Cermeño JC. Induction of apoptosis by cerebrospinal fluid from patients with primary-progressive multiple sclerosis in cultured neurons. Neurosci Lett 1998; 255: 75-8.
74. Alcázar A, Regidor I, Masjuan J, Salinas M, Álvarez-Cermeño JC. Axonal damage induced by cerebrospinal fluid from patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 2000; 104: 58-67.
75. 1 magnetic resonance imaging. J Neurol Sci 2002; 193: 103-9.
76. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50: 389-400.
77. Meyer R, Weissert R, Diem R, Storch MK, De Graaf KL, Kramer B, et al. Acute neuronal apoptosis in a rat model of multiple sclerosis. J Neurosci 2001; 21: 6214-20.
78. Andersson M, Álvarez-Cermeño JC, Bernardi G, Cogato I, Fredman P, Frederiksen J, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J Neurol Neurosurg Psychiatry 1994; 57: 897-902.
79. Gay FW, Drye TJ, Dick GWA, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Brain 1997; 120: 1461-83.
80. Genain GP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5: 170-5.
81. Zhu B, Moore GR, Zwimpfer TJ, Kastrukoff LF, Dyer JK, Steeves JD, et al, Axonal cytoskeleton changes in experimental optic neuritis. Brain Res 1999; 824: 204-17.
82. Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 2002; 168: 458-65.
83. Villar LV, Masjuan J, González-Porqué P, Plaza P, Sádaba MC, Roldán E, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002. (In press).
84. Niehaus A, Shi J, Grzenkowski M, Diers-Fenger M, Archelos J, Hartung H-P, et al. Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: Implications for remyelination. Ann Neurol 2000; 48: 362-71.
85. Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002; 346: 165-73.
86. Silber E, Semra YK, Gregson NA, Sharief MK. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002; 58: 1372-81.
87. Lee MK, Cleveland DW. Neuronal intermediate filaments (review). Ann Rev Neurosci 1996; 19: 187-217.
88. Brady ST, Witt AS, Kirkpatrick LL, de Waegh SM, Readhead C, Tu PH, et al. Formation of compact myelin is required for maturation of the axonal cytoskeleton. J Neurosci 1999; 18: 7278-88.
89. Gabern JY, Yool DA, Moore GJ, Wilds IB, Faulk MW, Klugmann M, et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 2002; 125: 551-61.
90. Semra YK, Seidi OA, Sarief MK. Heightened release of axonal cytoeskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002; 122: 132-9.
91. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117: 759-65.
92. Goodin DS, Frohman EM, Garmany Jr GP, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis. Neurology 2002; 58: 169-78.
93. Comi G, Martino G. Fundamento racional para el tratamiento precoz de la esclerosis múltiple. Rev Neurol 2000; 30: 1265-8.
94. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1 a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
95. Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, et al. Interferon β-1 a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002; 51: 481-90.
96. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 2001; 357: 1576-82.
97. Morrissey SP, Miller DH, Kendall BE, Kingsley DPE, Kelly MA, Francis DA, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Brain 1993; 116: 135-46.
98. Optic neuritis study group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 1997; 49: 1404-13.
99. CHAMPS Study group. Interferon β-1 a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 2001; 132: 1-9.
100. Freedman MS, Blumhardt LD, Brochet B, Comi G, Noseworthy JH, Sandberg-Wollheim M, et al. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler 2002; 8: 19-23.